The Food and Drug Administration (FDA) published a draft guidance document entitled "Guidance for Industry: Internal Radioactive Contamination-Development of Decorporation Agents" to help ensure that medical products called decorporation agents -- drugs that help eliminate radioactive materials from the body -- will be available to protect U.S. citizens from radiation contamination. The guidance provides advice on what studies sponsors need to perform to evaluate new decorporation agents in the hopes of getting these products approved by the FDA.
Decorporation agents reduce health risks by increasing the rate of elimination or excretion of radioactive contaminants that have been absorbed, inhaled or ingested.
"The guidance we are publishing today represents yet another step by the FDA to make medical countermeasures available to counteract potential acts of terrorism," said acting FDA Commissioner Dr. Lester M. Crawford. "Protecting Americans from attacks is a fundamental part of FDA's public health mission."
The draft document provides guidance to industry on the development of those decorporation agents for which evidence is needed to demonstrate effectiveness but for which human efficacy studies are unethical or not feasible.
FDA convened a multidisciplinary group of scientists to discuss how provisions under the Animal Efficacy Rule, which took effect in 2002, could be used to facilitate development of new decorporation agents. This rule applies when adequate and well-controlled clinical studies in humans cannot be ethically conducted because the studies would involve administering a potentially lethal or permanently disabling toxic substance or organism to healthy human volunteers. It is a major part of FDA's effort to help make medical countermeasures available and thereby help improve the nation's ability to respond to emergencies, including terrorist events.
Other examples of approved decorporation agents are Prussian blue, potassium iodide (KI), Ca-DTPA and Zn-DTPA. These drugs, when manufactured under conditions specified in an approved NDA, have been found safe and effective for the treatment of internal contamination with radioactive cesium (Prussian Blue), iodine (KI), and plutonium, americium, or curium(Ca-DTPA and Zn-DTPA).
Written comments on the draft guidance may be submitted up to 60 days from the date it is published in the Federal Register.
Comments should be sent to FDA's Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, Md. 20852.
Source: FDA
Dear Helpdesk: Working in a Toxic Health Care Environment
March 28th 2024Dear Helpdesk is your steadfast companion, offering life coaching and workplace advice from 2 seasoned IPs for some of your most challenging real-life situations. Let us help you navigate the intersection between work and life, guiding you to navigate the dynamic world of infection prevention with confidence and grace. This article is on handling a toxic health care environment.
Product Locator: Spring and Early Mother's Day Gift Guide for Infection Prevention Personnel
March 27th 2024Whether it's a spring holiday, birthdays, or no reason at all, infection prevention personnel love to give and receive gifts that help at the end of a stressful day. Infection Control Today® offers some gift ideas for infection prevention personnel and their families.
Catching Up With Vangie Dennis, AORN 2022-2023 President at AORN 2024
March 26th 2024Infection Control Today (ICT) had the privilege of catching up with Vangie Dennis, MSN, RN, CNOR, CMLSO, at the Association of periOperative Registered Nurses' (AORN’s) International Surgical Conference & Expo 2024. As the former president of AORN and an esteemed figure in perioperative services, Vangie Dennis shared insights into her recent endeavors and the exciting new chapter she's embarked upon.
How To Optimize Your Time Management Strategies for the Busy Infection Preventionist
March 25th 2024Is your calendar resembling a chaotic masterpiece of overlapping tasks? Join the club of infection preventionists striving to balance responsibilities. Dive into proven strategies from a fellow infection preventionist to reclaim control of your time, streamline tasks, and boost productivity effectively. This is an IP Lifeline article.